Abeona Therapeutics Inc. (ABEO) Stock Price Down 9.3%

Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price was down 9.3% on Thursday . The stock traded as low as $17.45 and last traded at $17.55. Approximately 1,809,143 shares changed hands during trading, an increase of 79% from the average daily volume of 1,010,060 shares. The stock had previously closed at $19.35.

Several equities analysts have weighed in on ABEO shares. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday, August 24th. BidaskClub downgraded shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th. Cantor Fitzgerald set a $21.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday, July 18th. Maxim Group reissued a “buy” rating and issued a $17.00 target price (up previously from $14.00) on shares of Abeona Therapeutics in a report on Tuesday, July 18th. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Abeona Therapeutics presently has a consensus rating of “Buy” and an average price target of $21.44.

The company has a 50-day moving average price of $15.16 and a 200-day moving average price of $8.64. The company’s market cap is $707.04 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million. On average, equities analysts predict that Abeona Therapeutics Inc. will post ($0.70) EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. Family Management Corp acquired a new stake in Abeona Therapeutics during the first quarter valued at $120,000. State of Wisconsin Investment Board acquired a new stake in Abeona Therapeutics during the second quarter valued at $122,000. Rhumbline Advisers acquired a new stake in Abeona Therapeutics during the second quarter valued at $190,000. Bank of New York Mellon Corp boosted its position in Abeona Therapeutics by 125.8% during the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 23,358 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Abeona Therapeutics during the second quarter valued at $264,000. 38.38% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics Inc. (ABEO) Stock Price Down 9.3%” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2956125/abeona-therapeutics-inc-abeo-stock-price-down-9-3.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.